Plasma Protein Therapeutics Association Europe, international Association without lucrative purpose

Tweet this page
<
2014
2015
2016
2017
2018
2019
2020
2021
2022
>
Registration as it was on 28 Nov 2022
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

400,000€ - 499,999€

Financial year: Jan 2021 - Dec 2021

Lobbyists (Full time equivalent)

3.75 Fte (6)

Lobbyists with EP accreditation

5

High-level Commission meetings

3

Lobbying Costs over the years

  • Info

    Plasma Protein Therapeutics Association Europe, international Association without lucrative purpose   (PPTA Europe aisbl)

    EU Transparency Register

    687559214721-11 First registered on 20 Oct 2014

    Goals / Remit

    As a trusted partner to health systems, PPTA drives broad and reliable access to high-quality plasma protein therapies, with a focus on the well-being of patients and plasma donors. We will strive to achieve our mission by:
    Fostering the collection of high-quality plasma from healthy donors;
    Establishing standards for the manufacturing of lifesaving plasma protein therapies at the highest levels of safety and quality;
    Breaking down artificial barriers on trade and compensated donors that limit patient access to therapy;
    Supporting government reimbursement practices that reflect the unique nature of plasma protein therapies;
    Educating all stakeholders about the value of the therapies; and
    Adhering to the PPTA Code of Ethics.

    Main EU files targeted

    Revision of DIRECTIVE 2002/98/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC

    Revision of DIRECTIVE 2004/23/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells

    EU Commission Proposal on EU Regulation on Substances of Human Origin, published on 14 July 2022

    EU Commission Evaluation of EU OMP Regulation and Paediatrics Regulation

    Revision of Directive 2001/83/EC Pharmaceuticals legislation - Pharma Code

    EU Pharmaceutical Strategy

    Address

    Head Office
    Boulevard Brand Whitlock, 114/4
    Brussels 1200
    BELGIUM
    EU Office
    Boulevard Brand Whitlock, 114/4
    Brussels 1200
    BELGIUM

    Website

  • People

    Total lobbyists declared

    6

    Employment timeLobbyists
    100%1
    75%2
    50%2
    25%1

    Lobbyists (Full time equivalent)

    3.75

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    5 accreditations were / are live (in bold) for the selected state of 01 Dec 2022

    Name Start date End Date
    Mr Maarten VAN BAELEN 28 Sep 2022 27 Sep 2023
    Mr Karl Petrovsky 27 Sep 2022 26 Sep 2023
    Ms Athina GIANNOUTSOU 24 Jun 2022 22 Jun 2023
    Ms Alexa WETZEL 24 Jun 2022 22 Jun 2023
    Ms Evelina KOZUBOVSKA 25 Mar 2022 24 Mar 2023
    Mr Karl Petrovsky 07 Oct 2021 06 Oct 2022
    Ms Athina GIANNOUTSOU 09 Jul 2021 08 Jul 2022
    Ms Alexa WETZEL 09 Jul 2021 08 Jul 2022
    Mr Maarten VAN BAELEN 09 Jul 2021 08 Jul 2022
    Mr Karl Petrovsky 16 Jan 2020 15 Jan 2021
    Mr Karl Petrovsky 23 Jan 2019 22 Jan 2020
    Mr Karl Petrovsky 30 Jan 2018 29 Jan 2019
    Mr Bruno Santoni 23 Jan 2017 19 Jan 2018
    Mr Karl Petrovsky 23 Jan 2017 16 Jan 2018
    Mr Bruno Santoni 02 Feb 2016 19 Jan 2017
    Mr Karl Petrovsky 02 Feb 2016 19 Jan 2017
    Mr Bruno Santoni 13 Feb 2015 11 Feb 2016
    Mr Karl Petrovsky 13 Feb 2015 11 Feb 2016

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Trade and business associations

  • Networking

    Affiliation

    EU Health Coalition, Brussels
    https://www.euhealthcoalition.eu/partners/

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2021 - Dec 2021

    Lobbying costs for closed financial year

    400,000€ - 499,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    rpp 50,000€ - 99,999€

    Intermediaries for current year

    Name
    bcw

    Closed year Costs

    400,000€ - 499,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    none

    Groups (European Parliament)

    N/A

    Other activities

    Healthcare - Pharmaceutical - Rare Diseases - Blood and blood component issues - Patient access to care with medicines/plasma protein therapeutics

  • Meetings

    Meetings

    3 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.

Download this datacard